Nevanac patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8071648 NOVARTIS Topical nepafenac formulations
Dec, 2025

(2 years from now)

US8324281 NOVARTIS Topical nepafenac formulations
Dec, 2025

(2 years from now)

US7834059 NOVARTIS Topical nepafenac formulations
Jan, 2027

(3 years from now)

Nevanac is owned by Novartis.

Nevanac contains Nepafenac.

Nevanac has a total of 3 drug patents out of which 0 drug patents have expired.

Nevanac was authorised for market use on 19 August, 2005.

Nevanac is available in suspension/drops;ophthalmic dosage forms.

Nevanac can be used as method of treating ocular inflammation.

The generics of Nevanac are possible to be released after 31 January, 2027.

Drugs and Companies using NEPAFENAC ingredient

Market Authorisation Date: 19 August, 2005

Treatment: Method of treating ocular inflammation


More Information on Dosage

NEVANAC family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic